Apogee Therapeutics Inc

Latest Results (11.10.2025):

In the first quarter of 2025, Apogee Therapeutics Inc reported a net loss of $55.3 million, reflecting increased investments in research and development as well as general and administrative expenses. The company's strong cash position of $681.4 million ensures operational sustainability into the first quarter of 2028, supporting ongoing pipeline advancements and clinical trials.

Cash Position

As of March 31, 2025, Apogee Therapeutics Inc maintained $681.4 million in cash, cash equivalents, and marketable securities. This robust financial standing is projected to fund the company's operations through the first quarter of 2028, providing a solid foundation for continued growth and development.

Research and Development Expenses

Research and development (R&D) expenses increased to $46.4 million for Q1 2025, up from $28.7 million in the same period of 2024. The rise in R&D spending is primarily driven by the advancement of Apogee’s pipeline and the expansion of its R&D team, reflecting the company's commitment to developing novel biologics for inflammatory and immunology markets.

General and Administrative Expenses

General and administrative (G&A) expenses rose to $16.7 million in Q1 2025 compared to $9.5 million in Q1 2024. This increase is attributed to higher personnel-related costs and equity-based compensation, resulting from the company's expanded operations and increased headcount to support business growth.

Net Loss

Apogee Therapeutics Inc reported a net loss of $55.3 million for the first quarter of 2025, up from a net loss of $32.1 million in Q1 2024. The increased net loss is mainly due to higher R&D and G&A expenses, partially offset by increased interest income.

Pipeline Progress

Despite the increased expenses, Apogee made significant strides in its pipeline, including positive interim results from the Phase 1b trial of APG808 for asthma and ongoing advancements in the Phase 2 APEX trial for atopic dermatitis. These developments highlight the company's potential for future revenue growth and market expansion.